NCT06547112View on ClinicalTrials.gov

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

July 23, 2025

Study Completion Date

August 19, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Motixafortide

Dose = 1.25 mg/kg via subcutaneous injection

DRUG

G-CSF

Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

BioLineRx, Ltd.

INDUSTRY

collaborator

Arvrmid Pharma

UNKNOWN

lead

Washington University School of Medicine

OTHER

NCT06547112 - A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization | Biotech Hunter | Biotech Hunter